DJS Law Group says investors may contact firm over Capricor securities class action

By Atlas Watchline Staff · Legal · August 17, 2026

DJS Law Group said investors may contact the firm about a securities class action that accuses Capricor Therapeutics of misleading statements tied to Deramiocel and a Biologics License Application.

DJS Law Group said in a PR Newswire release dated Aug. 17, 2026, that it is reminding investors about a securities class action against Capricor Therapeutics Inc., which trades on Nasdaq under the ticker CAPR. The release says the complaint alleges violations of Section 10(b), Section 20(a) and SEC Rule 10b-5.

The release says the class period runs from Dec. 17, 2025, through July 26, 2026. It says the complaint alleges Capricor made false and misleading statements to the market, modified the statistical analysis plan used for clinical data for Deramiocel, and did not secure FDA agreement to that change before resubmitting a Biologics License Application for the drug.

According to the release, the complaint says those issues made Capricor’s public statements false and materially misleading during the class period. The item does not include a response from Capricor.

The release also says shareholders who bought CAPR during the class period may contact DJS Law Group about possible lead plaintiff appointment. It says lead plaintiff status is not required to participate in any recovery and that investors who suffered a loss should contact the firm.

The release is attorney advertising and is not an independent court filing or government action. No court ruling, settlement or regulatory determination is described in the source material.

What happens next is a legal process that would depend on the complaint and any court schedule, but the release does not give a hearing date or other deadlines beyond the class period.

Sources

• PR Newswire release

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.